AI for Disease Prediction and Early Detection

Diagnosing a disease late often narrows the window of treatment; in cancer, the difference between early and late stage is often the difference in survival. Traditional screening programs are valuable but are tests applied to everyone at once, focused on one disease at a time. AI offers a different path: using the vast data already in existence — health records, lab values, imaging, and molecular profiles — to construct person-specific risk maps. The appeal of this approach lies in being able to focus on the people in whom risk is actually concentrated rather than applying the same test to everyone — that is, directing limited health-care resources to those most likely to benefit.

The Hidden Signal in Health Records

Electronic health records (EHRs) are a rich time series of visits, lab tests, diagnoses, and prescriptions accumulated over years. They contain both structured data (lab values, codes) and unstructured data (physician notes). Machine learning can pick up subtle patterns that the human eye would not notice in this volume of data.

One of the most promising applications is in pancreatic cancer — an insidious disease most often diagnosed late. Machine learning models trained on EHR data can flag high-risk individuals among those who do not yet have symptoms, generating a candidate pool for targeted early screening. Similarly, models predicting individual-level risk for melanoma and lung cancer from longitudinal (time-series) EHR data have been developed.

An important feature of these models is the ability, through natural language processing (NLP), to read unstructured physician notes. Nuanced phrases in a radiology report — "suspicious," "follow-up advised" — or patterns in clinical notes can carry signals that structured data would miss. AI converts this text into numeric features and feeds it into the risk model — bringing the years of observations a clinician has accumulated into a form the machine can also "read."

Not Just One Window — Multi-omic Integration

The future of early detection lies less in looking at a single data source and more in reading many layers together. The multi-omics approach integrates molecular data — genomics, transcriptomics, proteomics — with imaging-derived "radiomics" features and clinical records. The goal is to build a comprehensive digital twin of each patient.

The power of these integrated models has begun to be proven. For example, HECTOR, a multimodal deep-learning model that combines histology and clinical staging, outperformed the existing molecular-based gold standard in predicting distant recurrence in endometrial cancer. Combining multi-omic data from multicenter cohorts has enabled identification of molecular subtypes with different prognoses and the development of signatures that can predict immunotherapy response.

Data Layers in AI-Based Prediction

Beyond Cancer: Chronic Disease and Cardiovascular Risk

Predictive AI is not limited to oncology. Cardiovascular disease remains the leading cause of death globally, and risk prediction in this area has been part of clinical practice for decades. Classical scoring tools (based on a limited number of variables such as age, cholesterol, and blood pressure) are useful, but machine learning models can incorporate many more variables — lab trends, comorbidities, medications, even imaging findings — for a more nuanced estimate of risk.

Similarly, in insidiously progressing conditions such as type 2 diabetes, chronic kidney disease, and heart failure, models can flag high-risk individuals years before clinical disease becomes apparent. The value lies in opening a window for lifestyle intervention or preventive treatment that can change the disease's course. The underlying principle is the same as in cancer: read the still-silent risk from already-existing routine data.

A Realistic View: The Gap Between Promise and Evidence

However exciting the field is, much of current evidence comes from retrospective studies and single-center datasets. A model performing well on one hospital's data does not mean it will perform the same way in a different population or in prospective clinical use. Issues such as class imbalance (small numbers of patients with disease) in clinical datasets can mislead models.

Moreover, "risk prediction" does not, on its own, produce benefit; it gains value only when tied to an action — for example, directing a high-risk person to early screening and improving the outcome. Demonstrating this chain with clinical outcomes requires randomized, prospective studies. The risk of unnecessary anxiety and interventions triggered by false positives must also be part of the equation.

Another critical issue is explainability. When a model labels a patient as "high risk," the clinician must be able to see why; a "black-box" output without a clear rationale undermines clinical trust and accountability. Work in the field therefore prioritizes not only accuracy but also interpretable models that show which variables drove a given decision. In the end, AI is at its safest when it is not the one making the decision instead of the physician, but rather an ally that strengthens the physician's reasoning with transparent rationale.